Goodman Advisory Group LLC Increases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Goodman Advisory Group LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 40.9% during the second quarter, HoldingsChannel.com reports. The fund owned 465 shares of the medical research company’s stock after acquiring an additional 135 shares during the period. Goodman Advisory Group LLC’s holdings in Thermo Fisher Scientific were worth $257,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of TMO. Accretive Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 8.1% in the 4th quarter. Accretive Wealth Partners LLC now owns 640 shares of the medical research company’s stock worth $340,000 after acquiring an additional 48 shares during the last quarter. Aveo Capital Partners LLC increased its position in shares of Thermo Fisher Scientific by 9.7% in the fourth quarter. Aveo Capital Partners LLC now owns 816 shares of the medical research company’s stock worth $433,000 after purchasing an additional 72 shares during the last quarter. Gryphon Financial Partners LLC raised its stake in Thermo Fisher Scientific by 8.5% in the fourth quarter. Gryphon Financial Partners LLC now owns 1,484 shares of the medical research company’s stock valued at $794,000 after purchasing an additional 116 shares in the last quarter. Gold Investment Management Ltd. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $124,000. Finally, Dorsey & Whitney Trust CO LLC increased its holdings in shares of Thermo Fisher Scientific by 11.7% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,145 shares of the medical research company’s stock worth $2,200,000 after buying an additional 435 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on TMO. Raymond James upped their target price on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Royal Bank of Canada reissued an “outperform” rating and set a $767.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, September 20th. Wells Fargo & Company assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price target on the stock. Finally, TD Cowen boosted their price objective on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $647.78.

Thermo Fisher Scientific Trading Down 0.8 %

NYSE TMO opened at $614.42 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $627.88. The stock has a market cap of $234.71 billion, a P/E ratio of 39.41, a price-to-earnings-growth ratio of 3.88 and a beta of 0.78. The stock has a 50 day simple moving average of $606.08 and a two-hundred day simple moving average of $582.06.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter in the previous year, the business posted $5.15 earnings per share. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be given a dividend of $0.39 per share. The ex-dividend date is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.25%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CAO Joseph R. Holmes sold 860 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $611.03, for a total transaction of $525,485.80. Following the completion of the transaction, the chief accounting officer now owns 1,814 shares of the company’s stock, valued at approximately $1,108,408.42. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,084 shares of company stock valued at $14,094,292. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.